Comparison of antimicrobial susceptibility testing methods for aztreonam-avibactam against NDM-producing Enterobacterales clinical isolates
10 affiliations
- 1Genomics & Resistant Microbes Group (GeRM), Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile
- 2Multidisciplinary Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Santiago, Chile
- 3Surveillance, Epidemiology, and New Technologies for Infectious Emerging Threats (SENTINET), Santiago, Chile
- 4UC Irvine School of Medicine, Irvine, California, USA
- 5Hospital Padre Hurtado, Santiago, Chile
- 6Pontificia Universidad Católica de Chile, Santiago, Chile
- 7Hospital La Florida, Santiago, Chile
- 8Hospital Regional de Puerto Montt, Universidad San Sebastián, Puerto Montt, Chile
- 9Hospital Dipreca, Santiago, Chile
- 10The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Abstract
Aztreonam-avibactam (ATM-AVI) is a promising therapeutic for New Delhi metallo-β-lactamase-producing Enterobacterales (NDM-E) infections. We evaluated the performance of disk diffusion and gradient diffusion methods compared with reference broth microdilution (BMD) for ATM-AVI susceptibility testing. A total of 245 non-duplicate NDM-E isolates were included, collected from unique patients at hospitals in Chile and the United States between 2022 and 2024. Nine ATM-AVI non-susceptible isolates from a separate collection were added to enrich for resistant isolates, yielding a total of 254 isolates. Reference BMD was performed according to Clinical and Laboratory Standards Institute (CLSI) criteria. ATM-AVI disk diffusion and two gradient diffusion methods (ETEST and MIC Test Strip) were evaluated against BMD using categorical agreement, essential agreement, and CLSI-defined error rates. All 245 NDM-E isolates were susceptible to ATM-AVI (MIC ≤4/4 µg/mL), with MIC₅₀/₉₀ values of 0.25/4 and 1/4 µg/mL, respectively. The collection consisted of Klebsiella pneumoniae (71%), Enterobacter cloacae complex (21%), and Escherichia coli (8%). Predominant NDM alleles included blaNDM-1 and blaNDM-7. Disk diffusion demonstrated 98% categorical agreement (250/254), with four minor errors. Both gradient diffusion methods achieved 99% categorical agreement (252/254), with no very major or major errors and two minor errors. Essential agreement was 67% for ETEST and 85% for MIC Test Strip; both methods tended to underestimate ATM-AVI MICs relative to BMD. ATM-AVI demonstrated robust in vitro activity against a contemporary NDM-E cohort. Disk and gradient diffusion methods are practical alternatives to BMD for clinical laboratories.
Related
- Activity of aztreonam–avibactam and comparators against difficult-to-treat resistant Enterobacterales from United States medical centres (2020–24) †
- Longitudinal Multicenter Susceptibility Trends of Ceftazidime/Avibactam and Imipenem/Relebactam and Dose Optimization in Critically Ill Patients with Carbapenem-Resistant Enterobacterales Bloodstream Infections
- From sepsis to necrotizing enterocolitis with appendiceal perforation: a case report of successful salvage therapy with aztreonam–avibactam in an extremely preterm infant with NDM-producing Klebsiella pneumoniae
- Successful treatment of NDM-type carbapenemase-producing CRKP bacteremia and intra-abdominal infection in severe acute pancreatitis with aztreonam-avibactam: a case report
- In Vitro Activity of Eravacycline, Aztreonam-Avibactam, and Cefiderocol Against Multidrug-Resistant Gram-Negative Clinical Isolates from a Romanian Tertiary Hospital.
BibTeX
@article{rivas2026comparison,
title = {{Comparison of antimicrobial susceptibility testing methods for aztreonam-avibactam against NDM-producing Enterobacterales clinical isolates}},
author = {Lina Rivas and Lorena Díaz and Valeria Quiroz and Jose R. W. Martinez and Camila Solar and Ayesha Khan and Katherine Soto and Pamela Rojas Soto and Maria-Paz Acuña and María L. Rioseco and Margareta Mühlhauser and Yehudit Bergman and Patricia García and José M. Munita and Pranita D. Tamma},
journal = {Journal of Clinical Microbiology},
year = {2026},
month = oct,
doi = {10.1128/jcm.00797-26},
url = {https://doi.org/10.1128/jcm.00797-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comparison of antimicrobial susceptibility testing methods for aztreonam-avibactam against NDM-producing Enterobacterales clinical isolates
AU - Lina Rivas
AU - Lorena Díaz
AU - Valeria Quiroz
AU - Jose R. W. Martinez
AU - Camila Solar
AU - Ayesha Khan
AU - Katherine Soto
AU - Pamela Rojas Soto
AU - Maria-Paz Acuña
AU - María L. Rioseco
AU - Margareta Mühlhauser
AU - Yehudit Bergman
AU - Patricia García
AU - José M. Munita
AU - Pranita D. Tamma
PY - 2026
DA - 2026/10/12
JO - Journal of Clinical Microbiology
DO - 10.1128/jcm.00797-26
UR - https://doi.org/10.1128/jcm.00797-26
AB - Aztreonam-avibactam (ATM-AVI) is a promising therapeutic for New Delhi metallo-β-lactamase-producing Enterobacterales (NDM-E) infections. We evaluated the performance of disk diffusion and gradient diffusion methods compared with reference broth microdilution (BMD) for ATM-AVI susceptibility testing. A total of 245 non-duplicate NDM-E isolates were included, collected from unique patients at hospitals in Chile and the United States between 2022 and 2024. Nine ATM-AVI non-susceptible isolates from a separate collection were added to enrich for resistant isolates, yielding a total of 254 isolates. Reference BMD was performed according to Clinical and Laboratory Standards Institute (CLSI) criteria. ATM-AVI disk diffusion and two gradient diffusion methods (ETEST and MIC Test Strip) were evaluated against BMD using categorical agreement, essential agreement, and CLSI-defined error rates. All 245 NDM-E isolates were susceptible to ATM-AVI (MIC ≤4/4 µg/mL), with MIC₅₀/₉₀ values of 0.25/4 and 1/4 µg/mL, respectively. The collection consisted of Klebsiella pneumoniae (71%), Enterobacter cloacae complex (21%), and Escherichia coli (8%). Predominant NDM alleles included blaNDM-1 and blaNDM-7. Disk diffusion demonstrated 98% categorical agreement (250/254), with four minor errors. Both gradient diffusion methods achieved 99% categorical agreement (252/254), with no very major or major errors and two minor errors. Essential agreement was 67% for ETEST and 85% for MIC Test Strip; both methods tended to underestimate ATM-AVI MICs relative to BMD. ATM-AVI demonstrated robust in vitro activity against a contemporary NDM-E cohort. Disk and gradient diffusion methods are practical alternatives to BMD for clinical laboratories.
SN - 0095-1137
SN - 1098-660X
ER -